Literature DB >> 28127589

Neuroinflammation Induces Neurodegeneration.

D Kempuraj1, R Thangavel1, P A Natteru2, G P Selvakumar2, D Saeed2, H Zahoor2, S Zaheer2, S S Iyer1, A Zaheer1.   

Abstract

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Multiple Sclerosis (MS) are characterized by neuronal degeneration and neuronal death in specific regions of the central nervous system (CNS). In AD, neurons of the hippocampus and entorhinal cortex are the first to degenerate, whereas in PD, dopaminergic neurons in the substantia nigra degenerate. MS patients show destruction of the myelin sheath. Once the CNS neurons are damaged, they are unable to regenerate unlike any other tissue in the body. Neurodegeneration is mediated by inflammatory and neurotoxic mediators such as interleukin-1beta (IL-1β), IL-6, IL-8, IL-33, tumor necrosis factor-alpha (TNF-α), chemokine (C-C motif) ligand 2 (CCL2), CCL5, matrix metalloproteinase (MMPs), granulocyte macrophage colony-stimulating factor (GM-CSF), glia maturation factor (GMF), substance P, reactive oxygen species (ROS), reactive nitrogen species (RNS), mast cells-mediated histamine and proteases, protease activated receptor-2 (PAR-2), CD40, CD40L, CD88, intracellular Ca+ elevation, and activation of mitogen-activated protein kinases (MAPKs) and nuclear factor kappa-B (NF-kB). Activated microglia, astrocytes, neurons, T-cells and mast cells release these inflammatory mediators and mediate neuroinflammation and neurodegeneration in a vicious manner. Further, immune and inflammatory cells and inflammatory mediators from the periphery cross the defective blood-brain-barrier (BBB) and augment neuroinflammation. Though inflammation is crucial in the onset and the progression of neurodegenerative diseases, anti-inflammatory drugs do not provide significant therapeutic effects in these patients till date, as the disease pathogenesis is not yet clearly understood. In this review, we discuss the possible factors involved in neuroinflammation-mediated neurodegeneration.

Entities:  

Keywords:  Cytokine; Neurodegeneration; Neuroinflammation; Parkinson’s disease

Year:  2016        PMID: 28127589      PMCID: PMC5260818     

Source DB:  PubMed          Journal:  J Neurol Neurosurg Spine


  100 in total

Review 1.  New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?

Authors:  Margaret E Walker; Julianne K Hatfield; Melissa A Brown
Journal:  Biochim Biophys Acta       Date:  2011-02-25

2.  Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia.

Authors:  Hongquan Dong; Wei Zhang; Xiaoning Zeng; Gang Hu; Huiwen Zhang; Shaoheng He; Shu Zhang
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

3.  Hemichannels Are Required for Amyloid β-Peptide-Induced Degranulation and Are Activated in Brain Mast Cells of APPswe/PS1dE9 Mice.

Authors:  Paloma A Harcha; Aníbal Vargas; Chenju Yi; Annette A Koulakoff; Christian Giaume; Juan C Sáez
Journal:  J Neurosci       Date:  2015-06-24       Impact factor: 6.167

4.  Signaling pathways in the activation of mast cells cocultured with astrocytes and colocalization of both cells in experimental allergic encephalomyelitis.

Authors:  Dae Yong Kim; Dooil Jeoung; Jai Youl Ro
Journal:  J Immunol       Date:  2010-05-28       Impact factor: 5.422

Review 5.  The Role of Mast Cells in Alzheimer's Disease.

Authors:  Yasdani B Shaik-Dasthagirisaheb; Pio Conti
Journal:  Adv Clin Exp Med       Date:  2016 Jul-Aug       Impact factor: 1.727

Review 6.  Neuro-immune dysfunction during brain aging: new insights in microglial cell regulation.

Authors:  Stephanie M Matt; Rodney W Johnson
Journal:  Curr Opin Pharmacol       Date:  2015-11-18       Impact factor: 5.547

7.  Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia.

Authors:  Craig M McKittrick; Catherine E Lawrence; Hilary V O Carswell
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

8.  Dopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators.

Authors:  Duraisamy Kempuraj; Ramasamy Thangavel; Evert Yang; Sagar Pattani; Smita Zaheer; Donna A Santillan; Mark K Santillan; Asgar Zaheer
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

Review 9.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

Review 10.  Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases.

Authors:  Howard Prentice; Jigar Pravinchandra Modi; Jang-Yen Wu
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

View more
  151 in total

1.  Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis.

Authors:  Mei-Ting Song; Jie Ruan; Ru-Yi Zhang; Jie Deng; Zhan-Qiang Ma; Shi-Ping Ma
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

Review 2.  The Expanding Regulatory Mechanisms and Cellular Functions of Long Non-coding RNAs (lncRNAs) in Neuroinflammation.

Authors:  Shraddha Tripathi; Bakhya Shree; Stuti Mohapatra; Anirban Basu; Vivek Sharma
Journal:  Mol Neurobiol       Date:  2021-02-08       Impact factor: 5.590

3.  Leukemia Inhibitory Factor Represses GnRH Gene Expression via cFOS during Inflammation in Male Mice.

Authors:  Nancy M Lainez; Djurdjica Coss
Journal:  Neuroendocrinology       Date:  2019-01-10       Impact factor: 4.914

Review 4.  Brain-Resident T Cells Following Viral Infection.

Authors:  Sujata Prasad; James R Lokensgard
Journal:  Viral Immunol       Date:  2018-09-18       Impact factor: 2.257

Review 5.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

6.  Persistent Toxoplasma Infection of the Brain Induced Neurodegeneration Associated with Activation of Complement and Microglia.

Authors:  Ye Li; Emily G Severance; Raphael P Viscidi; Robert H Yolken; Jianchun Xiao
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

7.  A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Authors:  Jacopo Troisi; Annamaria Landolfi; Carmine Vitale; Katia Longo; Autilia Cozzolino; Massimo Squillante; Maria Cristina Savanelli; Paolo Barone; Marianna Amboni
Journal:  Metabolomics       Date:  2019-06-10       Impact factor: 4.290

8.  Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.

Authors:  Ramasamy Thangavel; Sachin M Bhagavan; Swathi Beladakere Ramaswamy; Spurthi Surpur; Raghav Govindarajan; Duraisamy Kempuraj; Smita Zaheer; Sudhanshu Raikwar; Mohammad E Ahmed; Govindhasamy Pushpavathi Selvakumar; Shankar S Iyer; Asgar Zaheer
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  In-depth characterization of the neuroinflammatory reaction induced by peripheral surgery in an animal model.

Authors:  Konstanze Plaschke; Sara Schulz; Rebecca Rullof; Markus A Weigand; Jürgen Kopitz
Journal:  J Neural Transm (Vienna)       Date:  2018-07-23       Impact factor: 3.575

10.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.